Bedrijfsoverzicht
Tenon Medical, Inc. is a specialized medical device company that focuses on the development of implants designed to treat severe lower back pain within the United States market. The firm's primary product offering includes the Catamaran SI-Joint Fusion System, which utilizes a titanium implant to address issues through an invasive approach targeting the sacroiliac joint. Operating within the broader Healthcare sector and specifically the Medical Devices industry, the company leverages its technological focus to address significant orthopedic challenges. The organization maintains a lean operational structure with 26 employees supporting its current business activities. As of the latest reporting period, the company holds a market capitalization of $8.69M and generated annual revenue of $3.94M. These financial figures indicate that Tenon Medical operates as a small-cap entity with limited revenue generation relative to its valuation, suggesting a position in an early-stage or niche market segment where market capitalization significantly exceeds current sales output.
Financiële gezondheid
The company reported revenue of $3.94M for the trailing twelve months, while simultaneously recording a net income loss of $12,556,000 and an EBITDA of $-11,756,000. The substantial gap between the positive revenue figure and the significant negative net income reveals a cost structure where operating expenses vastly outweigh revenue generation, indicating that the company is currently burning cash to fund its development and operational activities. Free cash flow stands at $-6,157,125, which highlights a lack of financial flexibility as the firm relies entirely on existing cash reserves or external financing to sustain operations without generating internal liquidity. The gross margin is reported at 59.8%, suggesting a high cost-efficiency in manufacturing or sourcing relative to sales price, yet this is negated by the operating margin of -193.5% and a profit margin of 0.0%, indicating severe operational inefficiencies or high administrative costs that prevent profitability. On the balance sheet, Tenon Medical holds $3.76M in cash against $141,000 in debt, resulting in a debt-to-equity ratio of 2.80, which reflects a highly leveraged position relative to equity despite the low absolute debt amount. The current ratio is 2.11, which indicates a healthy short-term liquidity position where current assets are more than double current liabilities, allowing the company to meet its immediate obligations without distress. Return on Equity is -228.1% and Return on Assets is -72.9%, metrics that reveal that management effectiveness is currently negative as the company destroys shareholder value and utilizes assets to generate losses rather than returns.
Waarderingsbeoordeling
Trailing P/E ratio is listed as N/A due to negative earnings, while the forward P/E is -1.23, a disparity that implies the market expects earnings to eventually turn positive but currently prices the stock based on future projections rather than historical profitability. The price-to-book ratio stands at 4.25, indicating a significant market premium over the company's book value, which often suggests high investor expectations for future growth or undervaluation of assets not captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 2.20 and an EV/EBITDA of -0.69 suggest that the market is valuing the firm on revenue multiples rather than earnings, a common practice for pre-profitable growth companies. The stock traded between a 52-week low of $0.64 and a 52-week high of $2.48, meaning the current price sits at a point that reflects significant volatility within this specific trading range. The beta value is 1.25, which means the stock price exhibits higher volatility relative to the broader market, moving more aggressively than the overall index during periods of market fluctuation.
Growth & Income
Revenue growth year-over-year reached 92.3%, whereas earnings growth is listed as N/A due to the company's ongoing losses, implying that top-line expansion is currently the primary driver of stock performance rather than bottom-line profitability. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, indicating that the firm retains all earnings to reinvest into research, development, and growth initiatives rather than distributing income to shareholders. The overall growth and income profile is characterized by explosive top-line expansion paired with a complete absence of dividend income, reflecting a strategy focused entirely on scaling the business and achieving future profitability. This profile aligns with the company's status as a small-cap medical device firm that must prioritize capital allocation toward product development and market penetration to overcome current operational losses.